265 related articles for article (PubMed ID: 18533800)
21. [Cytokine-based and targeted therapy of metastatic renal cell carcinoma--a current analysis].
Johannsen M; Ringsdorf M; Römer A; Loening SA; Roigas J
Aktuelle Urol; 2007 Jan; 38(1):38-45. PubMed ID: 17290328
[TBL] [Abstract][Full Text] [Related]
22. Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancer.
Porta C
Expert Rev Anticancer Ther; 2006 Jan; 6(1):141-52. PubMed ID: 16375651
[TBL] [Abstract][Full Text] [Related]
23. Presurgical therapy in metastatic renal cell carcinoma.
Jonasch E
Expert Rev Anticancer Ther; 2007 Jan; 7(1):73-8. PubMed ID: 17187521
[TBL] [Abstract][Full Text] [Related]
24. Improving outcomes in patients with advanced renal cell carcinoma.
Sosman JA
Expert Rev Anticancer Ther; 2008 Mar; 8(3):481-90. PubMed ID: 18366295
[TBL] [Abstract][Full Text] [Related]
25. EORTC-GU group expert opinion on metastatic renal cell cancer.
de Reijke TM; Bellmunt J; van Poppel H; Marreaud S; Aapro M
Eur J Cancer; 2009 Mar; 45(5):765-73. PubMed ID: 19157861
[TBL] [Abstract][Full Text] [Related]
26. Vaccine therapy in patients with renal cell carcinoma.
Van Poppel H; Joniau S; Van Gool SW
Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522
[TBL] [Abstract][Full Text] [Related]
27. Multimodality treatment paradigms for renal cell carcinoma: surgery versus targeted agents.
Köpke T; Bierer S; Wülfing C; Tiemann A; Hertle L; Herrmann E
Expert Rev Anticancer Ther; 2009 Jun; 9(6):763-71. PubMed ID: 19496713
[TBL] [Abstract][Full Text] [Related]
28. [Perioperative immune modulation in renal cell carcinoma--review of the current situation].
Böhm M; Klatte T; Allhoff EP
Aktuelle Urol; 2003 Sep; 34(5):319-27. PubMed ID: 14566659
[TBL] [Abstract][Full Text] [Related]
29. The role of cytoreductive nephrectomy for renal cell carcinoma in the era of targeted therapy.
Chowdhury S; Harper PG; Choueiri TK
Nat Clin Pract Oncol; 2008 Dec; 5(12):698-9. PubMed ID: 18852722
[No Abstract] [Full Text] [Related]
30. Can vaccination or tyrosine kinase inhibitor therapy play a role in the adjuvant treatment of renal cell carcinoma?
Brookman-May S; May M; Gilfrich C; Wieland WF; Burger M
Expert Rev Anticancer Ther; 2010 Jun; 10(6):813-23. PubMed ID: 20553207
[TBL] [Abstract][Full Text] [Related]
31. Cytoreductive nephrectomy in metastatic renal cell carcinoma.
Margulis V; Matin SF; Wood CG
Curr Opin Urol; 2008 Sep; 18(5):474-80. PubMed ID: 18670270
[TBL] [Abstract][Full Text] [Related]
32. Cytokine therapy: a standard of care for metastatic renal cell carcinoma?
Hutson TE; Quinn DI
Clin Genitourin Cancer; 2005 Dec; 4(3):181-6. PubMed ID: 16425986
[TBL] [Abstract][Full Text] [Related]
33. [Bilateral synchronous renal cell carcinoma: report of three cases].
Nakatsuji H; Yamashita Y; Karashima T; Hashine K; Sumiyoshi Y
Hinyokika Kiyo; 1999 Oct; 45(10):695-8. PubMed ID: 10586361
[TBL] [Abstract][Full Text] [Related]
34. [Immunotherapy in the management of metastatic renal carcinoma].
Fischetti G; Cuzari S; Leone P; De Martino P; Musy M; Mariani S; Fraioli A; Valentini MA
Minerva Urol Nefrol; 2002 Jun; 54(2):113-7. PubMed ID: 12070458
[TBL] [Abstract][Full Text] [Related]
35. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome.
Wood CG
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):697s-702s. PubMed ID: 17255296
[TBL] [Abstract][Full Text] [Related]
36. New drug therapies for advanced renal cell carcinoma.
Gore ME; Harrison ML; Montes A
Expert Rev Anticancer Ther; 2007 Jan; 7(1):57-71. PubMed ID: 17187520
[TBL] [Abstract][Full Text] [Related]
37. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma.
Atkins MB; Regan M; McDermott D
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6342S-6S. PubMed ID: 15448028
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease.
Wood CG; Margulis V
Cancer; 2009 May; 115(10 Suppl):2355-60. PubMed ID: 19402066
[TBL] [Abstract][Full Text] [Related]
39. Correspondence re: G. C. de Gast et al., Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. Clin. Cancer Res., 6: 1267-1272, 2000.
Meyers FJ; O' Donnell RT
Clin Cancer Res; 2000 Oct; 6(10):4167. PubMed ID: 11051273
[No Abstract] [Full Text] [Related]
40. Immunotherapy of metastatic renal cell carcinoma.
McDermott DF; Atkins MB
Cancer J; 2008; 14(5):320-4. PubMed ID: 18836337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
